Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,766.50
Bid: 1,766.00
Ask: 1,766.50
Change: 36.50 (2.11%)
Spread: 0.50 (0.028%)
Open: 1,735.50
High: 1,766.50
Low: 1,735.00
Prev. Close: 1,730.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS: Flutter Raised To Buy; Fresnillo Lowered To Sell

Mon, 08th Feb 2021 09:35

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

MORGAN STANLEY RAISES FLUTTER TO 'OVERWEIGHT' (EQUAL-WEIGHT) PRICE TARGET 17,400 (14,000) PENCE

----------

JEFFERIES CUTS UNILEVER PRICE TARGET TO 4,550 (5,350) PENCE - 'BUY'

----------

BARCLAYS CUTS UNILEVER PRICE TARGET TO 4,800 (5,500) PENCE - 'OVERWEIGHT'

----------

DZ BANK CUTS FAIR VALUE FOR UNILEVER TO 4,750 (4,850) PENCE - 'BUY'

----------

RBC RAISES JD SPORTS FASHION TO 'OUTPERFORM' (SECTOR PERFORM) - TARGET 950 (900) PENCE

----------

MORGAN STANLEY RAISES RECKITT BENCKISER PRICE TARGET TO 7,900 (7,800) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY RAISES IMPERIAL BRANDS TARGET TO 1,630 (1,600) PENCE - 'UNDERWEIGHT'

----------

UBS CUTS GLAXOSMITHKLINE PRICE TARGET TO 1,320 (1,450) PENCE - 'NEUTRAL'

----------

DZ BANK CUTS FAIR VALUE FOR GLAXOSMITHKLINE TO 1,550 (1,700) PENCE - 'BUY'

----------

CITIGROUP RAISES BHP GROUP PRICE TARGET TO 2,100 (2,000) PENCE - 'NEUTRAL'

----------

JPMORGAN RAISES ANGLO AMERICAN PRICE TARGET TO 3,000 (2,900) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS RIO TINTO PRICE TARGET TO 6,940 (7,000) PENCE - 'OVERWEIGHT'

----------

CITIGROUP RAISES RIO TINTO PRICE TARGET TO 6,000 (5,800) PENCE - 'BUY'

----------

BARCLAYS CUTS FRESNILLO PRICE TARGET TO 1,000 (1,100) PENCE - 'EQUAL WEIGHT'

----------

UBS CUTS FRESNILLO TO 'SELL' ('NEUTRAL') - TARGET 700 (1,100) PENCE

----------

BARCLAYS CUTS ANTOFAGASTA PRICE TARGET TO 1,050 (1,100) PENCE - 'UNDERWEIGHT'

----------

JEFFERIES RAISES PERSIMMON PRICE TARGET TO 3,349 (3,213) PENCE - 'BUY'

----------

JEFFERIES CUTS BARRATT DEVELOPMENTS TO 'HOLD' ('BUY') - TARGET 787 (772) PENCE

----------

BARCLAYS RAISES BARRATT DEVELOPMENTS TARGET TO 760 (725) PENCE - 'EQUAL WEIGHT'

----------

JEFFERIES RAISES TAYLOR WIMPEY TO 'BUY' ('HOLD') - TARGET 203 (156) PENCE

----------

GOLDMAN SACHS RAISES SEGRO PRICE TARGET TO 1,200 (1,110) PENCE - 'BUY'

----------

JEFFERIES RAISES SEGRO PRICE TARGET TO 999 (945) PENCE - 'HOLD'

----------

GOLDMAN RAISES NATWEST PRICE TARGET TO 270 (240) PENCE - 'BUY'

----------

GOLDMAN RAISES BARCLAYS PRICE TARGET TO 195 (180) PENCE - 'NEUTRAL'

----------

GOLDMAN RAISES LLOYDS BANKING TO 'NEUTRAL' (SELL) - PRICE TARGET 38 (33) PENCE

----------

FTSE 250

----------

PEEL HUNT INITIATES JUST GROUP WITH 'BUY' - TARGET 120 PENCE

----------

JEFFERIES RAISES VESUVIUS PRICE TARGET TO 575 (540) PENCE - 'BUY'

----------

JEFFERIES RAISES MORGAN ADVANCED MATERIALS TARGET TO 360 (300) PENCE - 'BUY'

----------

BERENBERG RAISES RENISHAW PRICE TARGET TO 6,600 (6,200) PENCE - 'BUY'

----------

BARCLAYS RAISES RENISHAW PRICE TARGET TO 5,185 (4,350) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY RAISES RENISHAW TARGET TO 5,100 (4,900) PENCE - 'EQUAL-WEIGHT'

----------

MORGAN STANLEY RAISES WEIR GROUP TO 'OVERWEIGHT' ('EQUAL-WEIGHT') - PRICE TARGET 2,200 (1,730) PENCE

----------

MORGAN STANLEY RAISES VICTREX PRICE TARGET TO 2,000 (1,700) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY RAISES SYNTHOMER TARGET TO 472 (380) PENCE - 'EQUAL-WEIGHT'

----------

BARCLAYS RAISES SPECTRIS PRICE TARGET TO 3,260 (2,940) PENCE - 'OVERWEIGHT'

----------

BARCLAYS RAISES KAZ MINERALS PRICE TARGET TO 900 (725) PENCE - 'OVERWEIGHT'

----------

RBC RAISES KAZ MINERALS PRICE TARGET TO 780 (640) PENCE - 'SECTOR PERFORM'

----------

GOLDMAN CUTS BABCOCK INTERNATIONAL PRICE TARGET TO 270 (290) PENCE - 'NEUTRAL'

----------

JEFFERIES RAISES MEGGITT PRICE TARGET TO 500 (375) PENCE - 'BUY'

----------

STIFEL EUROPE CUTS EASYJET TO 'SELL' (BUY) - PRICE TARGET 700 (600) PENCE

----------

RBC CUTS MARKS & SPENCER TO 'SECTOR PERFORM' (OUTPERFORM) - TARGET 150 (160) PENCE

----------

GOLDMAN RAISES ROYAL MAIL PRICE TARGET TO 470 (350) PENCE - 'BUY'

----------

JEFFERIES RAISES ROYAL MAIL PRICE TARGET TO 300 (145) PENCE - 'UNDERPERFORM'

----------

JEFFERIES RAISES BEAZLEY PRICE TARGET TO 475 (430) PENCE - 'BUY'

----------

RBC RAISES BEAZLEY PRICE TARGET TO 480 (410) PENCE - 'OUTPERFORM'

----------

PEEL HUNT CUTS LANCASHIRE HOLDINGS PRICE TARGET TO 720 (740) PENCE - 'HOLD'

----------

CREDIT SUISSE CUTS LANCASHIRE HOLDINGS TARGET TO 865 (895) PENCE - 'OUTPERFORM'

----------

GOLDMAN RAISES VIRGIN MONEY PRICE TARGET TO 155 (134) PENCE - 'NEUTRAL'

----------

JEFFERIES RAISES COUNTRYSIDE PROPERTIES PRICE TARGET TO 547 (497) PENCE - 'BUY'

----------

JEFFERIES RAISES BELLWAY PRICE TARGET TO 3,560 (3,288) PENCE - 'BUY'

----------

JPMORGAN RAISES CREST NICHOLSON PRICE TARGET TO 280 (260) PENCE - 'UNDERWEIGHT'

----------

OTHER MAIN MARKET AND AIM

----------

BARCLAYS RAISES SOUTH32 PRICE TARGET TO 130 (125) PENCE - 'UNDERWEIGHT'

----------

BARCLAYS RAISES GEM DIAMONDS PRICE TARGET TO 62 (55) PENCE - 'OVERWEIGHT'

----------

GOLDMAN RAISES THG PRICE TARGET TO 915 (885) PENCE - 'BUY'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more
26 Oct 2023 09:19

TOP NEWS: GSK subsidiary ViiV receives HIV drug approval in China

(Alliance News) - GSK PLC on Thursday said its subsidiary ViiV Healthcare has received marketing authorisation in China for its cabotegravir treatment, marketed as Vocabria.

Read more
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.